cyrilzakka/clinical-trials huggingface dataset:
Effect of Extracorporeal Shock Wave on Electrophysiological Changes and Pain in Patients With Lower Cross Syndrome

Lower Cross Syndrome happens when there is muscular imbalance between weak and tight muscles. The tight muscles are generally the hip flexors and erector spinae, and weak muscles are the abdominals and gluteal muscles. Shortening occurs in the hip flexors while weakening occurs in the abdominals and gluteal muscles.

Group I (Study): will consist of 22 patients with lower cross syndrome and will receive extracorporeal shock wave in addition to selected physical therapy program. For 12 sessions every other day, each session for 1 hour.

Group II (Control): will consist of 22 patients with lower cross syndrome and will receive selected physical therapy program only same as group (I). For 12 sessions every other day, each session for 1 hour.

Eligibility Criteria:
Inclusion Criteria:

1. Forty-four lower cross syndrome patients from both genders their ages ranged from 30-45 years old.
2. All patients in present study will be ambulant independently.
3. All patients will be medically stable.
4. The body mass index (BMI) will be ranged from 20:25 Kg/m2.

Exclusion Criteria:

1. Patients with musculoskeletal deformities and disorders.
2. Patients with psychiatric disorders or seizures.
3. Patients with visual and auditory impairment or tremors influencing balance.
4. Patients with other neuromuscular disorders.
5. Patients with BMI more than 25 kg/m2.
6. Patients with cognitive impairment.
7. Patients with lower limb or head and brain surgeries.
Whole Body Vibration Versus Functional Strength Training On Balance In Children With Hemiparetic Cerebral Palsy

The study will be directed to compare which of whole body vibration (WBV) training and Functional strength training (FST) has better effect on balance in children with hemiparesis

Hemiparesis is a type of hemiplegia where mild muscle weakness causes balance disturbances because one side of the body is affected such as the arm, chest leg or face.

Muscle weakness is commonly associated with abnormal bone development, leading to increased susceptibility to fractures, most cerebral palsy children have deficits in balance, coordination, and gait throughout childhood and adulthood. So, it is essential to seek an ideal physical therapy program to help in solving such widespread problem.

Balance control is important for competence in the performance of most functional skills, helping children to recover from unexpected balance disturbances, either due to slips and trips or to self- induced instability when making a movement that brings them toward the edge of their limit of stability Whole body vibration is mechanical oscillation, defined by amplitude and frequency, generates a force that acts on whole body. It is a training method for muscle tone modulation that is increasingly used in a variety of clinical situations.

Functional strength training (FST) is an effective method of exercise therapy. It can be combined with traditional physical therapy methods and can be successfully combined with most rehabilitation and exercise equipment. It provides postural stability while promoting independence with confidence.

The current study will be directed to compare which of whole body vibration (WBV) training and Functional strength training (FST) has better effect on balance in children with hemiparesis.

Eligibility Criteria:
Inclusion Criteria:

* The children in the study will be selected according to the following criteria:

  1. Their chronological age ranged from five to eight years old.
  2. Spasticity Grade I and II according to Modified Ashworth Scale.
  3. They will be on Level II and III according to Gross Motor Functional Classification System (GMFCS)
  4. Have the ability to walk independently.
  5. They can understand order and follow instruction.
  6. The child will be able to follow verbal commands and instructions.
  7. They can firmly grasp the rails of biodex device.

Exclusion Criteria:

1. Children with visual or auditory problems.
2. Children with uncontrolled convulsions.
3. Children with fixed contractures and deformities.
4. Children with surgical intervention less than one year.
5. Children injected by BOTOX in the calf muscle from less than one year.
6. Children had heart disease.
7. Children with epilepsy.
8. Children with severe diabetes.
9. Children with severe vascular disease
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients

This is an open-label, single ascending dose study to evaluate safety, tolerability, and pharmacokinetics/pharmacodynamics of Tripegfilgrastim in pediatric solid tumor/lymphoma patients


Eligibility Criteria:
Inclusion Criteria:

* \>=6 and \<19-year-old pediatrics with solid tumor/lymphoma
* Scheduled for chemotherapy requiring G-CSF support or having given an experience of ANC \< 0.5x10\^9/L
* ANC \> 0.75x10\^9/L, platelet \> 75x10\^9/L
* ECOG performance status 0 or 1

Exclusion Criteria:

* Patients with leukemia, myelodysplastic syndrome or uncontrolled infectious/nervous diseases
* History of allergy to filgrastim, pegfilgrastim or known hypersensitivity to E-coli derived proteins.
* Women who are pregnant or lactating
TACE as an Adjuvant Therapy After Hepatectomy for HCC

Investigators hypothesise that the use of transarterial chemoembolisation (TACE) after liver resection in patients with hepatocellular carcinoma can eradicate residual cancer cells in the liver and thus improve survival of patients with high risk factors for residual tumor. The aim of this study is to compare the survival of patients with high risk factors for residual tumor undergoing liver resection plus post-operative TACE versus liver resection alone.

Liver resection is the mainstay of curative treatment for hepatocellular carcinoma (HCC). However, recurrence is common after surgery and most occurs in the liver, especially for the patients with high risk factors for residual tumor, such as tumors with a diameter more than 5 cm, multiple nodules, and microvascular invasion. Transarterial chemoembolisation (TACE) is an effective palliative treatment for HCC. It involves the infusion of chemotherapeutic agent admixed with iodised oil followed by embolisation of the hepatic arterial flow using small particles. This procedures allows application of smaller dose of chemotherapy concentrated to the liver and thus is well tolerated with minimal side effects. The main complications of TACE are liver function damage, mild feverish symptoms, vomit , etc. But most of them are reversible.

We conduct a randomised controlled trial evaluating the efficacy of using TACE after hepatectomy in HCC patients with high risk factors for residual tumor (tumors with a diameter more than 5 cm, multiple nodules, or microvascular invasion).

Eligibility Criteria:
Inclusion Criteria:

* HCC patients received curative hepatectomy with negative resection margin
* Tumors with a diameter more than 5 cm, multiple nodules, or microvascular invasion were defined as high risk factors for residual tumor and used for patient stratification.
* Age from 18 to 70
* Child-Pugh class A
* ASA class I to III
* ECOG performance status Grade 0 or 1

Exclusion Criteria:

* Patients receiving concomitant local ablation or previous TACE
* Main portal vein tumour thrombus extraction during hepatectomy
* Tumour arising from caudate lobe
* Presence of extra-hepatic disease
* Impaired liver function with either clinically detected ascites, hepatic encephalopathy, serum albumin \< 25g/L or bilirubin \> 50micromol/L
* Renal impairment with creatinine \> 200micromol/L
* Severe concurrent medical illness persisting \> 6 weeks after hepatectomy
* History of other cancer
* Hepatic artery anomaly making TACE not possible
* Allergy to doxorubicin or lipiodol
* Pregnant woman
* Informed consent not available
Implementation of a Primary Hospital Provider (PHP) Team

The goal of this pragmatic clinical trial is to learn if it is possible to implement a Primary Hospital Provider (PHP) team that aims to improve continuity of care for patients who are frequently hospitalized. The main question it aims to answer is: Are patients assigned to the PHP team more likely to be assigned to this team during a follow up hospitalization? Researchers will compare this to similar patients assigned to receive usual care. Some participants from both the PHP team and usual care groups will be asked to participate in interviews to help researchers understand the needs of patients who are frequently admitted and the care they receive.


Eligibility Criteria:
Inclusion Criteria:

* Age greater than 18 at the time of index admission
* Two or more hospitalizations to a general medicine service at UW Health (University Hospital or East Madison Hospital) within the past 12 months AND an EPIC Readmission Risk Score of greater than a predetermined value

Exclusion Criteria:

* Outpatient primary care provider is part of the UW Health Family Medicine service that currently admits their own patients to a separate service at University Hospital
* Patients with an oncologic diagnosis for which they are actively receiving chemotherapy or immunotherapy
* Prisoners
* Pregnant women
Retrospective Study of Keloid Disorder

Purpose of this retrospective study is to review and analyze the information and data that has been already been generated during the course of routine practice of medicine by the investigators from 2007 up until Sept 1, 2016 from keloid patients who have sought medical care or medical advice for their keloid disorder.

To retrospectively review and analyze clinical data that has already been collected from keloid patients including photographs taken of keloid lesions during routine practice of medicine by the investigators 1) To better understand natural history of keloid disorder (KD), 2)To determine the ethnic incidence and prevalence of keloid, 3) To determine the rate of familial keloids, 4) To determine response to different treatment modalities, 5) To determine risk factors for development and worsening of keloid lesions.

Eligibility Criteria:
Inclusion Criteria:

* All patients must have at least one keloid lesion.
* Availability of photographic documentation of keloid lesion(s).

Exclusion Criteria:

* Lack of photographic documentation of keloid lesion(s)
* Lack of demographic data
Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old

Evaluate safety and immunogenicity of three influenza vaccines in children ages greater than 4 years old to less than 18 years old.


Eligibility Criteria:
Inclusion Criteria:

1. Male or female aged 4 years to less than 18 years of age.
2. Individual who had a parent or guardian who could give written informed consent after understanding the nature of the study and comply with study procedures and were available for follow-up.
3. If the individual was of an age where, according to local regulations, informed assent is required, that individual had provided assent to participate in the study.

Exclusion Criteria:

1. Individuals recently vaccinated against influenza
2. Subjects with contraindications to receive influenza vaccine
A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC

This was a Phase 2, randomized, multicenter, open-label, 2-arm study to investigate the efficacy and safety of ociperlimab in combination with tislelizumab plus BAT1706, and tislelizumab plus BAT1706, as first-line treatment in participants with advanced Hepatocellular Carcinoma (HCC).


Eligibility Criteria:
Criteria:

Inclusion Criteria:

1. Histologically confirmed HCC
2. Barcelona Clinic Liver Cancer (BCLC) Stage C disease, or BCLC Stage B disease that was not amenable to or had progressed after loco-regional therapy, and was not amenable to a curative treatment approach
3. Tumor tissue required for an evaluable programmed cell death protein-ligand 1 (PD-L1) expression result
4. No prior systemic therapy for HCC
5. At least 1 measurable lesion as defined per RECIST v1.1
6. Adequate organ function during screening and before randomization

Exclusion Criteria:

1. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC histology
2. Prior therapy with antibody or drug specifically targeting T-cell costimulation or checkpoint pathway; prior treatment with bevacizumab or its biosimilars
3. Prior history of \>= Grade 2 hepatic encephalopathy
4. Leptomeningeal disease or uncontrolled, untreated brain metastasis
5. Active autoimmune diseases or history of autoimmune diseases that may relapse
6. History of interstitial lung disease, non-infectious pneumonitis or uncontrolled lung diseases including pulmonary fibrosis, acute lung diseases
7. Infection (including tuberculosis) requiring systemic antibacterial, antifungal, or antiviral therapy within 14 days of randomization
8. Prior allogeneic stem cell transplantation or organ transplantation
9. Significant cardiovascular risk factors
10. Untreated or incompletely treated esophageal or gastric varices with bleeding or high risk of bleeding
11. History of severe hypersensitivity reactions to other monoclonal antibodies
12. Administered a live vaccine \<=28 days before randomization

NOTE: Other protocol Inclusion/Exclusion criteria may apply
Prophylactic Noninvasive Ventilation in vs Postoperative Standard Care in High Risk Patients According to ARISCAT Score

Postoperative pulmonary complications are one of the most common complications after surgery.

Noninvasive ventilation has been proposed post-operatively to prevent postoperative pulmonary complications.

Prophylactic noninvasive ventilation performed systematically in a non-specific population is without interest.

The difficulty for the practitioner is to target patients at higher risk of developing a postoperative pulmonary complications in order to guiding them to a post-operative specialized care pathway.

The use of the ARISCAT score, validated on a large European prospective cohort, makes it possible to evaluate, preoperatively, the risk of occurrence of postoperative pulmonary complication in the patient.

The hypothesis of the present research is that early postoperative preventive treatment with noninvasive ventilation, in patients at risk of postoperative pulmonary complications according to the preoperative evaluation according to the ARISCAT score, could have an interest in reducing these complications with a superior efficiency over standard techniques.

After verification of eligibility criteria and ARISCAT score, patients at high risk of COPD are randomized in the study.

At the exit of the operating room, patients are referred to the services according to their randomization arm :

* arm with prophylactic noninvasive ventilation in intensive care unit. Patients will receive noninvasive ventilation for a maximum of 48 hours. Sessions last 1 hour and are repeated every 2 to 3 hours
* arm with standard care in conventional care unit. Patients receive standard care such as physiotherapy.

In both arms, patient follow-up is 7 days maximum.

Eligibility Criteria:
Inclusion Criteria:

* Patient 18 years of age or older
* Patient scheduled for surgery or considered semi-urgent (=pre-anesthesia consultation \<48h before the surgical procedure) under General Anesthesia or under Loco-Regional Anesthesia
* Patient with an ARISCAT score higher than or equal to 45 - Obtaining the signed written consent of the patient
* Patient affiliated to a social security scheme

Exclusion Criteria:

* Minor patients, pregnant or lactating women
* Obstetrical interventions
* Surgery under Local Anesthesia or Peripheral Nerve,
* Interventions taking place outside an interventional room
* Interventions for previous surgical complications
* Second surgery during study
* Organ transplantation
* Patients already intubated in preoperative
* Outpatient surgery
* Refusal of participation or inability to issue informed consent
* Person deprived of liberty or adult under guardianship
* Participation in another interventional study
CRIC Combined With MFT for Cardiovascular Adverse Events in Patients With Incomplete Revascularization of CAD

The main objective of this study is to demonstrate whether the combination of chronic remote ischemic conditioning and mindfulness therapy can reduce cardiovascular adverse events in patients with incomplete revascularization of coronary artery disease.


Eligibility Criteria:
Inclusion Criteria:

* 1) Age ≥18 years old
* 2) Consistent with the diagnosis of coronary heart disease, complete revascularization was not performed (coronary angiography showed that at least one vessel with a reference diameter of 3.0mm had stenosis greater than 90%, and quantitative flow ratio (QFR) \< 0.80)
* 3) Symptoms of myocardial ischemia (resting or exertional angina; Angina allele: chest tightness, shortness of breath, etc.);

Exclusion Criteria:

* Age \< 18 years old
* Heart failure patients with NYHA class IV, or left ventricular ejection fraction (LVEF) \< 40%
* Creatinine clearance \< 30 mL/min (or eGFR \< 30 mL/min/1.73m²), or requires dialysis
* Myocardial diseases such as hypertrophic cardiomyopathy, dilated cardiomyopathy, etc.
* Uncontrolled or recurrent arrhythmic events (e.g., ventricular fibrillation, recurrent or symptomatic sustained ventricular tachycardia, complete heart block, atrial fibrillation with rapid ventricular rates, supraventricular tachycardia refractory to drugs)
* Poorly controlled hypertension (SBP \> 180 mm Hg or DBP \> 110 mm Hg)
* Active liver disease or persistent ALT or AST elevation ≥ 3 times the upper limit of normal
* Unexplained CK \> 5 times the upper limit of normal, or elevated CK due to known muscle disease
* Planned or anticipated cardiac surgery or revascularization before randomization
* History of active malignancy (surgery, radiation therapy, and/or systemic therapy within the past 3 years)
* Diagnosed or suspected upper extremity vascular malformations, aneurysms, arteriovenous fistulas, or thrombosis
* Hearing impairment, unable to undergo mindfulness therapy
* Currently participating in another drug or device study, or within 30 days of completing another drug or device study or receiving another investigational drug
* Any life-threatening comorbid conditions expected to result in death within the next year (excluding cardiovascular diseases)
* Alcoholism, substance abuse history; and unwilling or unable to stop alcohol or substance abuse during the study
* History of major organ transplant (e.g., lung, liver, heart, bone marrow, kidney)
* Investigator's judgment of known major active and uncontrolled disease, or any medical, physical, or surgical conditions (e.g., infection, significant blood, kidney, metabolic, gastrointestinal, or endocrine dysfunction) that may interfere with participation in the clinical study
* As known to the investigator, the subject is unlikely to complete follow-up for more than 1 year or is expected to be unable to comply with the study requirements or understand the study's objectives and potential risks.
Vibrotactile Coordinated Reset for Parkinson's Patients of a More Variable Population

The purpose of our study is to evaluate Vibrotactile Coordinated Reset stimulation (vCR) and its effects on Parkinson's symptoms of a more variable population. vCR will be administered with a device called the Stanford Glove. vCR is expected to provide patients with a non-invasive alternative to the most widely used treatments such as Levodopa and or deep brain stimulation. Patients will be followed for two years.


Eligibility Criteria:
Inclusion Criteria:

1. Age at the time of enrollment: 35 - 92 years
2. Idiopathic Parkinson's Symptoms between Hoehn and Yahr stages 2 to
3. Fluent in English
4. Comfortable with technology; can use a computer, check email, and access the internet; can initiate and engage in a virtual meeting for training and monitoring purposes.
5. Feels comfortable going off PD related medication during in person study visits
6. Lives in the United States

Exclusion Criteria:

1. Any significant neuro-psychiatric problems, including acute confusional state, ongoing psychosis, or suicidal tendencies
2. Any current drug or alcohol abuse.
3. Participation in another drug, device, or biologics trial concurrently or within the preceding 30 days. Any other trial participation should be approved by the Principal Investigators.
4. Pregnancy, breast-feeding or wanting to become pregnant
5. Craniotomy
6. Brain surgery
7. Patient is unable to communicate properly with staff (i.e., severe speech problems)
8. Excessive drooling
9. Patient is taking a medication that may cause significant withdrawal effects
A Randomized-Controlled Trial to Investigate the Effect of a Novel Music Therapy Application to Reduce Anxiety and Stress

This virtual, open-label, three-group, randomized-controlled trial will last six weeks. Participants will be allocated into three groups; the Intervention Group, Spotify Group, and Control Group. All participants will complete a baseline questionnaire before completing their designated regime daily for six weeks. In addition, participants will complete study-specific surveys and validated questionnaires at the end of each week (Week 1, 2, 3, 4, 5 \& 6). The study will include 75 \[participants in total, 25 per group, who all have self-reported concerns around anxiety, stress, or depression.

Questionnaires will be used to monitor sleep, cognitive ability, and changes in symptoms of anxiety, depression, and stress. Both study-specific questionnaires and validated questionnaires will be utilized, including the Generalized Anxiety Disorder Assessment (GAD-7), the 9-question Patient Health Questionnaire (PHQ-9), Perceived Stress Scale (PSS), and The World Health Organisation- Five Well-Being Index (WHO-5). Likert scale responses will be examined from baseline to each check-in. Participant responses on product feedback will be presented as % scores.


Eligibility Criteria:
Inclusion Criteria:

* Male or female
* Between 18-28 years of age
* Self-reported concerns around anxiety, stress, or depression
* Generally healthy - don't live with any uncontrolled chronic disease
* Must have headphones

Exclusion Criteria:

* Any pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders
* Women who are pregnant, breastfeeding or attempting to become pregnant
* Unwilling to follow the study protocol
* Testing any other product for any other research studies at the same time
* History of epilepsy or seizures